Modality
Fusion Protein
MOA
FcRni
Target
Nectin-4
Pathway
Amyloid
ALSMesoCervical Ca
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
~Feb 2017
→ ~May 2018
Phase 3
Aug 2018
→ Oct 2027
Phase 3Current
NCT06111163
2,433 pts·Cervical Ca
2018-08→2026-01·Terminated
NCT06675265
641 pts·ALS
2020-09→2027-10·Not yet recruiting
NCT05990497
1,265 pts·Cervical Ca
2025-10→2025-05·Not yet recruiting
4,339 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-05-0111mo agoPh3 Readout· Cervical Ca
2026-01-182mo agoPh3 Readout· Cervical Ca
2027-10-201.6y awayPh3 Readout· ALS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Termina…
P3
Not yet…
P3
Not yet…
Catalysts
Ph3 Readout
2025-05-01 · 11mo ago
Cervical Ca
Ph3 Readout
2026-01-18 · 2mo ago
Cervical Ca
Ph3 Readout
2027-10-20 · 1.6y away
ALS
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06111163 | Phase 3 | Cervical Ca | Terminated | 2433 | VA |
| NCT06675265 | Phase 3 | ALS | Not yet recr... | 641 | UPCR |
| NCT05990497 | Phase 3 | Cervical Ca | Not yet recr... | 1265 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 | |
| IDY-3466 | Ideaya Bio | NDA/BLA | Nectin-4 |